Showing 1 - 10 of 50
Persistent link: https://www.econbiz.de/10003483796
Persistent link: https://www.econbiz.de/10012060924
Persistent link: https://www.econbiz.de/10012060929
Persistent link: https://www.econbiz.de/10012060932
The paper reviews the existing cost-sharing practices in four Central European countries namely the Czech Republic, Hungary, Poland and Slovakia focusing on patient co-payments for pharmaceuticals and services covered by the social health insurance. The aim is to examine the role of cost-sharing...
Persistent link: https://www.econbiz.de/10010125435
In 2010, a household survey was carried out in Hungary among 1037 respondents to study consumer preferences and willingness to pay for health care services. In this paper, we use the data from the discrete choice experiments included in the survey, to elicit the preferences of health care...
Persistent link: https://www.econbiz.de/10010125436
Persistent link: https://www.econbiz.de/10010434928
INTRODUCTION: Prostate cancer, the most frequent malignant disease in males in Europe, accounts for a great proportion of health expenditures. AIM: A systematic review of registry-based studies about the cost-of-illness and related factors of prostate cancer, published in the last 10 years....
Persistent link: https://www.econbiz.de/10010434936
OBJECTIVES: To compare the efficacy and safety of infliximab-biosimilar with other biological drugs for the treatment of active ankylosing spondylitis (AS). METHODS: Systematic literature review for randomized controlled trials (RCTs) with adalimumab, etanercept, golimumab, infliximab and...
Persistent link: https://www.econbiz.de/10010434939
OBJECTIVE: The aim of this meta-analysis was to compare the efficacy and safety of infliximab-biosimilar and other available biologicals for the treatment of rheumatoid arthritis (RA), namely abatacept, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, rituximab and tocilizumab....
Persistent link: https://www.econbiz.de/10010434940